Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

497 - Concomitant chemoradiation using gemcitabine in locally advanced head and neck cancer


20 Dec 2015


Poster presentation 2


Quratul-Ain Hashmi


Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527


Q. Hashmi1, A. Mateen2

Author affiliations

  • 1 Clinical Oncology, Al-Khaliq Hospital, Nishtar Road, Multan, 60000 - Multan/PK
  • 2 Clinical Oncology, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR)-Nishtar Hospital, 60000 - Multan/PK


Abstract 497


The current treatment of head and neck squamous cell carcinoma (HNSCC) has high toxicity rate, so an alternate protocol is necessary to increase the chance of disease control. The rationale of the present study is to assess the response rate, disease free survival and median survival of concomitant chemoradiation using gemcitabine in locally advanced HNSCC.


Eighty three (83) patients with locally advanced HNSCC were enrolled. Gemcitabine in a dose of 100 mg/m2 was given once weekly during external beam radiotherapy (ERT). ERT was delivered using 60Co upto 66 Gy, 2 Gy/fraction/day limiting spinal cord dose to 44 Gy. Response was assessed by computed tomography at six weeks. Response to therapy was assessed through clinical examination and computed tomography (CT) at two months from start of treatment. The primary endpoint was to assess disease-free survival (DFS) and overall survival (OS).


Complete response (CR) was seen in 44 (53%), partial response (PR) in 29 (35%), stable disease (SD) in 5 (6%) patients and progressive disease in 5 (6%) patients. There was no statistically significant difference in combined CR and PR between male (84%) and female (89%), and according to age. There was significant difference (P-value < 0.05) in combined CR and PR between stage III (93%) and IV patients (79%). Four year DFS and OS were 38% and 51%, respectively. Mean and median DFS (year) were 2.17 ± 0.16 (95% confidence interval [CI] 1.86 to 2.48) and 1.70 ± 0.24 (95% CI 1.23 to 2.17), respectively. Mean and median OS (year) were 2.97 ± 0.16 (95% CI 2.66 to 3.28) and 3.01 ± 0.19 (95% CI 2.82 to 3.26), respectively.


This study showed that concomitant chemoradiation using gemcitabine has a high response rate and fairly good DFS and OS even in advanced HNSCC, especially in stage III patients.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings